Elizabeth C. Hsia

5.3k citations

109 papers · 3.9k indexed · 3 hit papers · h-index 34

Rheumatology top 0.1%
- Rheumatoid Arthritis Research and Therapies 67
- Spondyloarthritis Studies and Treatments 40
- Systemic Lupus Erythematosus Research 20
Hematology top 0.5%
- Autoimmune and Inflammatory Disorders Research 53
Immunology top 1%
- Psoriasis: Treatment and Pathogenesis 36
Genetics top 2%
- Chronic Lymphocytic Leukemia Research 24
Dermatology top 2%
- Dermatology and Skin Diseases 6
Pathology and Forensic Medicine
- Lymphoma Diagnosis and Treatment 7

Co-authors: Mahboob U. Rahman Jonathan Kay Eric L. Matteson Mittie K. Doyle Sudha Visvanathan Yiying Zhou Roy Fleischmann Atul Deodhar
Cited by: Rheumatology Hematology Immunology
Partner nations: United States United Kingdom Canada

In The Last Decade

Elizabeth C. Hsia

106 papers receiving 3.8k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2020 Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
2020 Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
2009 Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

Peers

Countries citing papers authored by Elizabeth C. Hsia

Since Specialization

Citations

This map shows the geographic impact of Elizabeth C. Hsia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elizabeth C. Hsia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elizabeth C. Hsia more than expected).

Fields of papers citing papers by Elizabeth C. Hsia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elizabeth C. Hsia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elizabeth C. Hsia. The network helps show where Elizabeth C. Hsia may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Elizabeth C. Hsia, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Elizabeth C. Hsia Line = papers co-authored together Elizabeth C. Hsia links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Guselkumab Modulates Differentially Expressed Genes in Blood of Patients With Psoriatic Arthritis: Results from Two Phase 3, Randomized, Placebo‐Controlled Trials Stefan Siebert,Kristen Sweet,Christopher T. Ritchlin,Elizabeth C. Hsia,Alexa P. Kollmeier,Xie L. Xu,Loqmane Seridi,Qingxuan Song,Sheng Gao,Warner Chen,Michelle Miron	2023	2
2	Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis M. Elaine Husni,Atul Deodhar,Sergio Schwartzman,Soumya D. Chakravarty,Elizabeth C. Hsia,Jocelyn H. Leu,Yiying Zhou,Kim Hung Lo,Arthur Kavanaugh	2022	11
3	Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis Atul Deodhar,Soumya D. Chakravarty,Natalie J. Shiff,Kim Hung Lo,Stephen Xu,Elizabeth C. Hsia,Abhijeet Danve,John D. Reveille	2022	1
4	The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial Alexis Ogdie,Jessica A. Walsh,Soumya D. Chakravarty,Steven L. Peterson,Kim Hung Lo,Lilianne Kim,Nan Li,Elizabeth C. Hsia,Eric K. H. Chan,Arthur Kavanaugh,M. Elaine Husni	2021	3
5	Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III, Randomized, Double‐Blind, Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis Iain B. McInnes,Proton Rahman,Alice B. Gottlieb,Elizabeth C. Hsia,Alexa P. Kollmeier,Xie L. Xu,Yusang Jiang,Shihong Sheng,M. Shawi,Soumya D. Chakravarty,Désirée van der Heijde,Philip J. Mease	2021	66
6	Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced Christopher T. Ritchlin,Philip Helliwell,Wolf‐Henning Boehncke,Enrique R. Soriano,Elizabeth C. Hsia,Alexa P. Kollmeier,Soumya D. Chakravarty,Federico Zazzetti,Ramanand A. Subramanian,Xie L. Xu,Qing Zuraw,Shihong Sheng,Yusang Jiang,Prasheen Agarwal,Bei Zhou,Yanli Zhuang,M. Shawi,Chetan S. Karyekar,Atul Deodhar	2021	50
7	Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis Iain B. McInnes,Proton Rahman,Alice B. Gottlieb,Elizabeth C. Hsia,Alexa P. Kollmeier,Soumya D. Chakravarty,Xie L. Xu,Ramanand A. Subramanian,Prasheen Agarwal,Shihong Sheng,Yusang Jiang,Bei Zhou,Yanli Zhuang,Désirée van der Heijde,Philip J. Mease	2020	56
8	Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study Philip J. Mease,M. Elaine Husni,Soumya D. Chakravarty,Shelly Kafka,Dennis Parenti,Lilianne Kim,Kim Hung Lo,Elizabeth C. Hsia,Arthur Kavanaugh	2020	9
9	Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients with Ankylosing Spondylitis: 28-Week Results of the GO-ALIVE Trial John D. Reveille,Atul Deodhar,Akgun Ince,Eric K. H. Chan,Steven L. Peterson,Nan Li,Elizabeth C. Hsia,Lilianne Kim,Kim Hung Lo,Stephen Xu,Diane D. Harrison,Chenglong Han	2020	6
10	Effects of Intravenous Golimumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial M. Elaine Husni,Arthur Kavanaugh,Eric K. H. Chan,Steven L. Peterson,Nan Li,Elizabeth C. Hsia,Lilianne Kim,Kim Hung Lo,Diane D. Harrison,Chenglong Han	2020	4
11	Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial Philip J. Mease,M. Elaine Husni,Shelly Kafka,Soumya D. Chakravarty,Diane D. Harrison,Kim Hung Lo,Stephen Xu,Elizabeth C. Hsia,Arthur Kavanaugh	2020	6
12	Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis M. Elaine Husni,Arthur Kavanaugh,Frederick T. Murphy,Д. Г. Рекалов,Diane D. Harrison,Lilianne Kim,Kim Hung Lo,Jocelyn H. Leu,Elizabeth C. Hsia	2019	16
13	Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial Edward Keystone,Mark C. Genovese,Stephen Hall,Sang‐Cheol Bae,Chenglong Han,Timothy Gathany,Stephen Xu,Yiying Zhou,Jocelyn H. Leu,Elizabeth C. Hsia	2015	35
14	The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis Daniel E. Fürst,Jonathan Kay,Mary Chester Wasko,Edward Keystone,Arthur Kavanaugh,Atul Deodhar,Frederick T. Murphy,Jeanette H. Magnus,Elizabeth C. Hsia,Benjamin Hsu,Stephen Xu,Mahboob U. Rahman,Mittie K. Doyle	2013	26
15	Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial Joshua F. Baker,Mikkel Østergaard,Paul Emery,Elizabeth C. Hsia,Jiandong Lu,Daniel G. Baker,Philip G. Conaghan	2013	57
16	Improvements in Physical Function, Health Related Quality of Life and Work Productivity in Patients with Rheumatoid Arthritis Treated with Golimumab: Sub-Analysis of Latin American Patients Enrolled in Mulitcentre Phase III Clinical Trials Ingrid Strusberg,Bernardo A. Pons‐Estel,Pedro C. Miranda,Mark C. Genovese,Roy Fleischmann,Andrea Puig,Chenglong Han,Elizabeth C. Hsia	2013	1
17	Golimumab in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results Through 2 Years of the GO-FORWARD Study Extension Edward Keystone,Mark C. Genovese,Stephen Hall,Pedro C. Miranda,Sang‐Cheol Bae,William Palmer,Wu Zhong,Stephen Xu,Elizabeth C. Hsia	2013	33
18	Paediatric and Adolescent Rheumatology [213-214] Paul Emery,Roy Fleischmann,Larry W. Moreland,Elizabeth C. Hsia,W. Xu,M Rahman	2009	1
19	Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trialbreakdown → Josef S Smolen,Jonathan Kay,Mittie K. Doyle,Robert Landewé,Eric L. Matteson,J. Wollenhaupt,Norman Gaylis,Frederick T. Murphy,Jeffrey Neal,Yiying Zhou,Sudha Visvanathan,Elizabeth C. Hsia,Mahboob U. Rahman	2009	423
20	Management of Aortic Disease in Marfan Syndrome Seoyoung C. Kim,Neil A. Martin,Elizabeth C. Hsia,Reed E. Pyeritz,Daniel Albert	2005	33

About Elizabeth C. Hsia

Elizabeth C. Hsia is a scholar working on Rheumatology, Hematology and Genetics, having authored 109 papers that have together received 3.9k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (67 papers), Autoimmune and Inflammatory Disorders Research (53 papers), Spondyloarthritis Studies and Treatments (40 papers), Psoriasis: Treatment and Pathogenesis (36 papers), Chronic Lymphocytic Leukemia Research (24 papers), Systemic Lupus Erythematosus Research (20 papers), Lymphoma Diagnosis and Treatment (7 papers) and Dermatology and Skin Diseases (6 papers). The work is most often cited by research in Rheumatology (3.1k citations), Hematology (1.6k citations) and Immunology (1.7k citations). Elizabeth C. Hsia has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Mahboob U. Rahman, Jonathan Kay, Eric L. Matteson, Mittie K. Doyle, Sudha Visvanathan, Yiying Zhou, Roy Fleischmann, Atul Deodhar, Alexa P. Kollmeier and Paul Emery.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact